◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral OPTIONAL-ADD LOW

Nefiracetam

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD LOW

Mechanistically interesting "anti-apathy + anxiolytic-flavored racetam" with one positive Phase 2 apathy substudy (Robinson 2009, post-stroke depression cohort, n=70, 900mg arm) — but the headline post-stroke depression Phase 2 (Robinson 2008, n=159) MISSED its primary endpoint, the 2016 Starkstein replication for post-stroke apathy was underpowered (n=13) and negative, Daiichi withdrew its Japanese NDA in 2002 for insufficient efficacy, and there are zero healthy-young-adult cognitive-enhancement RCTs. For Dylan-archetype: rarely the right call vs better-evidenced racetams (pramiracetam for memory/focus, aniracetam for mood-anxiolytic flavor); only consider if specifically chasing the apathy/motivation phenotype and other Russian dopaminergics (bromantane, sulbutiamine) under-deliver. Confidence would jump to MEDIUM only if a healthy-adult cognitive-enhancement RCT replicates the apathy-Scale signal in a non-stroke population.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD

    / PRN, LOW confidence. Anti-apathy + motivation phenotype is interesting but Dylan does not have an apathy problem. Already adding modafinil + bromantane in V5 — both deliver motivation more reliably. Reasonable PRN to keep in the optional drawer for low-motivation valleys or as a low-key racetam trial pre-V5 stack. Not a daily driver. Pramiracetam (memory/focus) and aniracetam (mood/anxiolytic) are higher-priority racetam picks for this archetype.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    Same logic; if exec is fighting apathy/motivation specifically, nefiracetam's niche fits. Otherwise, pramiracetam first.

  • 50+, mild cognitive decline, post-stroke, or apathy-dominant presentation
    OPTIONAL-ADD

    with stronger rationale. Cleanest evidence is the Robinson 2009 apathy signal in this exact population. If apathy is the dominant phenotype (not depression, not memory loss alone), 900 mg/day TID nefiracetam for 8-12 weeks is a defensible trial. Failed Starkstein 2016 replication is a yellow flag but underpowered.

  • Post-stroke depression (specific)
    STRONG-CANDIDATE

    in Japan / Asia historically; current evidence: ADJUNCT-NOT-MONOTHERAPY. Robinson 2008 missed primary; Daiichi withdrew Japanese NDA 2002. Current consensus places nefiracetam as an *adjunctive* possibility for the apathy-component of post-stroke depression, not a monotherapy. Standard-of-care SSRIs remain first-line.

  • Anxiety-prone
    OPTIONAL-ADD

    GABA_A agonism gives mild anxiolytic flavor. Aniracetam (AMPA-route mood) and fasoracetam (GABA_B + glutamate) are both better-evidenced anxiolytic racetams. Nefiracetam less acutely felt.

  • High athletic load, tested status
    OPTIONAL-ADD

    Not on WADA panel as of 2026-05. Compatible with training — no stim, no sleep disruption at standard doses. Untested status irrelevant for Dylan.

  • Sleep-disordered
    NEUTRAL

    Mild GABA_A could in theory smooth sleep onset if dosed late; opposite case (cholinergic activation delaying sleep) also possible. Not a sleep aid; dose mid-day at most.

  • Recovery-focused (post-injury, post-illness, post-concussion)
    OPTIONAL-ADD

    with theoretical rationale. BDNF/CREB upregulation + cholinergic/glutamatergic circuit support is mechanistically attractive for post-concussive recovery. Cerebrolysin has actual TBI clinical data; nefiracetam does not. Cerebrolysin first; nefiracetam as adjunct if cerebrolysin response is partial.

  • Strength/anabolic-focused
    SKIP

    wrong domain. Not anabolic; theoretical androgen-pathway concern from dog testicular tox findings, though human relevance is essentially zero (M-18 metabolite not formed in humans, monkey studies clean).

▸ Subjective experience (deep)

Onset and timecourse:

  • Tmax ~2 hours after oral dose (food-enhanced absorption, fat-soluble)
  • Half-life 3-5 hours; metabolites have longer t1/2 (4-22 hours)
  • Acute single-dose effects: minimal to none for most users. Unlike phenylpiracetam (felt within 1-2 hours) or modafinil, nefiracetam is a "build-up" molecule.
  • Days 1-7: Often nothing. Occasional mild headache (choline-deficit-related); rare GI discomfort.
  • Week 2-4: The "nefiracetam phenotype" emerges — calm focus, reduced mental friction, motivation lift, less apathy/inertia. Verbal fluency reportedly improved. Mild anxiolytic background (the GABA_A piece).
  • Cycle / discontinuation: Effects fade over 1-2 weeks post-stop; no documented withdrawal or rebound.

Phenotype vs other racetams (community + mechanism-derived):

Racetam Dominant phenotype Best for Where nefiracetam differs
Piracetam Subtle baseline lift, weak Newcomers, baseline Nefiracetam is more potent + has GABA_A flavor
Aniracetam Mood-bright, anxiolytic via AMPA, sociable Anxious users, social settings Aniracetam is more felt acutely; nefiracetam is slower and more anti-apathy than anti-anxiety
Oxiracetam Logical, energetic, less mood Analytical work Nefiracetam is calmer, less stim
Pramiracetam Strong memory/focus, choline-hungry Heavy cognitive load Pramiracetam is sharper-edged; nefiracetam softer + motivational
Phenylpiracetam Stim-like + dopamine, fast tolerance One-off exam/training day Phenylpiracetam is acutely felt; nefiracetam isn't
Coluracetam HACU + reported visual enhancement Niche visual / depression-anxiety Both less felt than aniracetam; nefiracetam better motivation, coluracetam more depression-target
Fasoracetam GABA-B + glutamate; anxiolytic-mood ADHD-w-anxiety subset, kids w/ comorbidity Fasoracetam is more anti-anxiety / mGluR-side; nefiracetam is GABA_A-anti-apathy

Honest expectation-setting for Dylan-archetype: This is not a "feel something" molecule. The clean racetam comparison: pramiracetam will deliver a more reliable subjective working-memory + focus lift; aniracetam will deliver more reliable mood/anxiolytic effect; nefiracetam's distinctive niche is anti-apathy / motivation — and Dylan does not have an apathy problem. He's already a high-motivation 20yo on track to add modafinil + bromantane (both aggressive motivation-side stim). Nefiracetam's signal would likely be noise on top of that stack.

The use case where nefiracetam wins for Dylan-archetype is pre-modafinil/bromantane onboarding as a low-key racetam trial, OR brief PRN use during a low-motivation valley where bromantane is in a wash-off period. Marginal use case; not load-bearing.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Minimal documented. Mechanistically, persistent CREB/BDNF/synaptic changes argue against acute receptor desensitization (unlike phenylpiracetam where dopamine-side tolerance is fast). Long-term tolerance unmapped — no human chronic-dosing studies beyond ~12 weeks.
  • Recommended cycle: No published rationale. Conservative pattern: 4-8 weeks on, 2-4 weeks off. Cycle for two reasons: (a) preserve tolerance buffer, (b) detect effect-vs-no-effect by contrast with off-cycle baseline.
  • Reset protocol: 2-4 weeks off should fully restore baseline. No reset adjuncts documented or needed.
▸ Stacking deep dive

Synergistic with

  • pramiracetam: Mechanistically complementary — pramiracetam dominates choline uptake / cholinergic memory side, nefiracetam adds GABA_A + motivation. Some community users run both. Both choline-hungry; ensure adequate citicoline + alpha-GPC. Theoretical; no clinical data.
  • aniracetam: AMPA-mediated mood + nefiracetam GABA_A modulation = anxiolytic stack. Sociability / mood + anti-apathy. Theoretical complement.
  • fasoracetam: Both have GABA-flavored anxiolytic profile but different receptors (GABA_A vs GABA_B). Stack rationale weak; might be redundant.
  • alcar / Cognizin citicoline: Acetylcholine substrate support — required for any racetam stack. Already in Dylan's V4.
  • cerebrolysin: Cerebrolysin provides exogenous neurotrophic peptides; nefiracetam upregulates endogenous BDNF via CREB. Theoretically complementary, particularly post-stroke / TBI. No clinical data.
  • bromantane: Bromantane = dopaminergic anti-asthenia; nefiracetam = GABAergic anti-apathy. Both target motivation by orthogonal pathways. Theoretical synergy for "low-motivation" phenotype.
  • modafinil: No documented interaction. Orthogonal mechanism (orexin/histamine vs racetam multi-target). Modafinil daytime + nefiracetam BID-TID with last dose mid-afternoon would be a coherent stack.

Avoid stacking with

  • High-dose benzodiazepines / Z-drugs (chronic): Theoretical GABA_A receptor competition — nefiracetam is a GABA_A agonist with significant binding affinity; chronic BZD use complicates the receptor state. Limited clinical concern but worth flagging.
  • Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, grapefruit at chronic doses): Nefiracetam 5-OH metabolism is CYP3A4-dominant. Strong inhibitors raise nefiracetam exposure; titrate down or avoid combination.
  • Other racetams stacked at full doses simultaneously: Diminishing returns + cumulative choline depletion → headache cascade. Pick one primary racetam.
  • NSAIDs (chronic high-dose) + dehydration: Theoretical compounding of any (very low) renal risk. Probably negligible in humans but conservative.

Neutral / safe co-administration

  • All of Dylan's V4 stack: DHA, magnesium glycinate/threonate, NAC, phosphatidylserine, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C, creatine — no documented interactions
  • Caffeine — no interaction
  • Russian peptides (semax, selank, adamax, bromantane) — no documented interaction; complementary mechanisms
  • Modafinil, armodafinil — no documented interaction
  • Cerebrolysin — no documented interaction
▸ Drug interactions deep dive
  • CYP3A4: Major metabolic pathway for 5-hydroxynefiracetam formation. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, grapefruit juice in large/chronic quantities) raise nefiracetam exposure. Strong inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) may lower exposure.
  • CYP1A2: Minor contribution to 5-OH metabolite formation. Heavy smoking / cruciferous-vegetable induction has unknown but probably-minimal effect.
  • CYP2C19: Capable of forming 5-OH metabolite (likely minor pathway). Genotype effects unmapped clinically.
  • Hormonal contraceptives: No documented interaction. Should be safe (unlike modafinil which induces CYP3A4 and reduces contraceptive efficacy).
  • Anticoagulants: No documented interaction signal.
  • Alcohol: No documented direct interaction. Alcohol's GI irritation may compound nausea early in dosing. Nefiracetam is documented as protective against ethanol-induced amnesia in animals — clinical relevance unclear.
▸ Pharmacogenomics
  • CYP3A4 expression / activity polymorphisms — relevant given CYP3A4 dominates 5-OH metabolite formation. CYP3A4 poor-metabolizer phenotypes are rare and not well characterized; CYP3A5*3 carriers (the common loss-of-function variant) likely have minimal effect on nefiracetam exposure since CYP3A4 dominates.
  • *CYP1A2 (rs762551, 1F): Heavy-inducer allele in smokers / heavy-coffee-drinkers; minor relevance given CYP1A2's minor pathway role.
  • **CYP2C19 2/3 (poor metabolizers, common in East Asians ~15-20%, Caucasians ~3%): Could subtly affect 5-OH formation; clinical relevance probably negligible.
  • No documented response-prediction PGx. Nothing in the published literature stratifies nefiracetam response by genotype.
  • 23andMe coverage: CYP3A4, CYP1A2 (rs762551), CYP2C19 (*2/*3) all covered. Once Dylan's 23andMe results land (~June 2026), worth pulling these out of routine curiosity but unlikely to change dosing.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem Science.bio (now BC9.co / successor) Powder; ~$25-50 per 25-50g Medium-high (third-party COA standard) US-based; historical reputation good; ID-verification practices vary.
Research-chem Pure Rawz Powder ~$30-60 per equivalent gram count; 99.9% claimed purity Medium (3rd-party tested per site) "Not for human consumption" disclaimer standard.
Research-chem Modern Aminos / Amino USA 100-200 mg unit packages; ~$20-40 for 10 g equivalent Medium Smaller vendors; verify COA per batch.
Research-chem Lab Pro / Tocris / Sigma / MedChemExpress / Cayman $100-300 for analytical mg quantities; CAS 77191-36-7 High (analytical-grade, COA standard) Designed for in-vitro work; price-prohibitive for personal dosing; identity unimpeachable.
Gray-market pharma Some Indian/Asian online pharmacies historically listed Translon (brand) Variable, intermittent stock Low-medium Daiichi never approved Translon — any "Translon" branded product is questionable provenance. Treat as research-chem.
Rx None (no approved indication globally) — — —

Approximate monthly cost at 450 mg/day (150 mg TID):

  • 13.5 g/month × ~$2-4/g research-chem = $25-40/month (matches user spec)
  • At 900 mg/day: ~$50-80/month

Sourcing notes:

  • Powder form requires accurate microgram scale (0.001 g resolution). At 150 mg per dose, a 0.01 g resolution scale is acceptable.
  • Tablet/capsule forms (when available) eliminate weighing risk.
  • Identity verification: niche compound + low-volume vendors = higher risk of mislabeling than for popular research-chems. Demand batch-specific COA. For a fully cautious approach, run a parallel analytical-grade reference from MedChemExpress through an HPLC service if accessible.
  • Dylan-archetype guidance: Order tablets/capsules from a 3rd-party-tested vendor (BC9 / Pure Rawz tier) with COA. Don't bother with bulk powder for an OPTIONAL-ADD trial.
▸ Biomarkers to track (deep)

Baseline (before starting)

  • Apathy Scale (14-item Marin/Starkstein) self-rated — primary outcome measure if running this for apathy
  • Hamilton Depression Rating Scale or PHQ-9 if mood-coupled
  • Working memory: N-back (1/2/3), CNS Vital Signs, or Cambridge Brain Sciences full panel
  • Subjective VAS for motivation, focus, anxiety, mood, energy (baseline × 7 days for averaging)
  • Liver panel (ALT, AST, ALP, GGT, bilirubin) — though human hepatotoxicity is not a documented concern, baseline + 8-week recheck is cheap insurance given the persistent (and likely-incorrect) "rat hepatotoxicity" folklore
  • Renal panel (creatinine, BUN, eGFR) + urinalysis — kidney watch given dog renal papillary necrosis finding (unlikely in humans but baseline is cheap)

During use

  • Apathy Scale + motivation VAS weekly
  • Subjective: focus, anxiety, mood, headache, sleep daily for first 2 weeks, then weekly
  • Cognitive battery at week 4 and week 8

Post-cycle

  • Apathy Scale + cognitive battery 1-2 weeks post-stop (residual / regression to baseline)
  • Liver + renal panel at week 8 if continued past 4 weeks
▸ Controversies / open debates Live debate

1. The "rat hepatotoxicity" claim — appears to be folklore misattribution

The claim: Various nootropics blogs and some user briefs reference "historical rat hepatotoxicity" as a safety concern for nefiracetam.

The actual literature: Standard rat oral toxicity studies of nefiracetam (chronic dosing) did not document hepatotoxicity as a primary finding. The historical animal-tox safety signal that delayed nefiracetam's regulatory path was:

  • Beagle dogs: Renal papillary necrosis at 90-300 mg/kg/day (mediated by the dog-specific M-18 metabolite which inhibits renal-papillary prostaglandin synthesis); testicular toxicity (hypospermatogenesis, seminiferous atrophy) at 60-180 mg/kg/day
  • Rats: Testicular toxicity at much higher doses than dogs; no renal papillary necrosis; no documented hepatotoxicity primary finding

Why this matters: The "rat hepatotoxicity" warning circulating in the nootropics community appears to be (a) confused with the rat testicular finding, (b) confused with the dog renal/testicular findings, or (c) simply transcribed wrong from one blog to another and propagated. There is no published rat hepatotoxicity finding I can identify from the standard tox-study literature in 2026-05.

Human translation: The dog M-18 metabolite is not formed in humans. Human urinary metabolite profiles match monkeys (which do not show renal or testicular toxicity). Long-term human safety data from clinical trials (12-week dosing at up to 900 mg/day) showed no significant hepatic, renal, or gonadal signal. The human safety profile in trials is clean.

Accuracy flag for this file: The user-supplied prompt referenced "rat hepatotoxicity flagged historically" — this appears inaccurate. The verified historical safety concerns are dog renal papillary necrosis + dog testicular toxicity, both species-specific via M-18 metabolite which humans don't form. Treat any "rat hepatotoxicity" claim with skepticism unless someone can produce the original tox study citation.

2. Robinson 2008 primary endpoint missed — what does the apathy-substudy positive signal mean?

The 2008 stroke-depression Phase 2 (n=159) missed its primary HDRS endpoint. The 2009 apathy substudy (n=70 with apathy) found a positive Apathy Scale effect at 900 mg only. Three interpretations:

  1. True effect, wrong primary endpoint. Nefiracetam works for apathy but not for depression-broadly; Daiichi picked the wrong primary. Argues for re-running with apathy-specific primary (which Starkstein 2016 attempted but couldn't enroll).
  2. Subgroup chance finding. Multiple-comparison inflation in a primary-negative trial; the apathy signal would not replicate. Starkstein 2016's null is consistent with this (though severely underpowered).
  3. Population-narrow effect. Nefiracetam works only in a specific phenotype (post-stroke + significant baseline apathy + 900 mg dosing) and the right trial has never been run.

Resolution: Nobody is running the right trial. Daiichi withdrew. Neuren Pharmaceuticals briefly held nefiracetam IP but no recent pipeline activity. The question is unresolved and probably will remain so.

3. Why has development stalled globally?

  • Daiichi (originator): Withdrew Japanese NDA Feb 2002; effectively abandoned program.
  • US/Canada Phase 2 (Robinson, NIH-funded): Concluded with mixed results 2008-2009; no Phase 3 follow-up funded.
  • Australia Phase 2 (Starkstein): Severely under-enrolled 2010-2014, published null 2016.
  • Neuren Pharmaceuticals: Listed as IP holder per pipeline aggregator (Synapse PatSnap). No active development.
  • No 2020-2026 trial activity registered anywhere.

The compound is mechanistically interesting and "almost worked" for a niche indication (post-stroke apathy at 900 mg) but never got a properly-powered Phase 3 readout. It now lives in regulatory limbo: discontinued by originator, not picked up by any major pharma, and only available as a research chemical.

4. Is nefiracetam really an "anti-apathy" molecule, or are users projecting?

The community phenotype (anti-apathy, motivation lift, calm focus) lines up with:

  • Mechanism (cholinergic + glutamatergic + GABA_A modulation = circuit activation + anxiolytic)
  • The single positive substudy (Robinson 2009 apathy)

But the community phenotype is also vulnerable to expectancy / confirmation bias because that's what the marketing says it does. There's no placebo-controlled subjective-rating study in healthy adults. Honest assessment: probably real but with a non-trivial expectancy contribution.

5. Does the GABA_A agonism actually translate to "feel-different" anxiolysis?

IC50 8.5 nM at GABA_A is comparable to clinically active benzodiazepines at the molecular level — but partial agonism + the multi-target profile means the clinical anxiolytic effect is modest at standard doses. Most users do not describe nefiracetam as a benzo-replacement. The GABA_A piece appears to contribute the "calm" descriptor users use rather than full anxiolysis.

6. Sourcing identity verification

Niche compound, low community surveillance, tablet/capsule sources less reliable than for popular research-chems. Vendor mislabeling is a real risk. Demand batch-specific COA. If running this seriously, run an analytical-grade reference comparison.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: OPTIONAL-ADD (PRN), LOW confidence. Rationale: Anti-apathy / motivation-flavored racetam with one positive Phase 2 substudy (Robinson 2009) and three less-positive trials (Robinson 2008 primary negative, Starkstein 2016 underpowered negative, Daiichi Japanese Phase 3 retrials insufficient efficacy → 2002 NDA withdrawal). Mechanism is uniquely interesting among racetams (only one with high-affinity GABA_A agonism). For Dylan-archetype, rarely the right call vs pramiracetam (memory/focus) or aniracetam (mood/anxiolytic) — but worth keeping in optional drawer for the specific motivation/apathy use case. Hepatotoxicity claim from prompt appears to be misattribution; actual historical safety concerns are dog-specific (renal papillary necrosis + testicular tox via M-18 metabolite, which humans don't form). Human clinical safety in trials clean.
▸ Open questions / gaps Open
  • Properly-powered apathy RCT in healthy adults or non-stroke clinical populations. Doesn't exist. Would resolve whether Robinson 2009 was a true effect.
  • Healthy-young-adult cognitive-enhancement RCT. None exist. All cognitive-enhancement claims for nefiracetam in healthy adults are anecdotal.
  • Long-term human safety data (>12 weeks). No published trials; chronic use is self-experimental.
  • Standard rat oral tox study primary findings — do any document hepatotoxicity? Re-verify whether the "rat hepatotoxicity" folklore has any genuine origin in the regulatory literature, or is purely transcription error. Current best understanding: it's transcription error.
  • Why the 600 mg arm did nothing in Robinson 2009 apathy substudy but 900 mg worked. Suggests narrow effective dose window; dose-response unmapped between 600-900 mg/day.
  • Combination data with cerebrolysin in post-stroke recovery. Theoretically attractive; clinically untested.
  • Nefiracetam in TBI / post-concussive recovery. Mechanistically plausible (BDNF/CREB upregulation), animal stroke data positive, no human TBI trial.
  • Active development? Neuren Pharmaceuticals listed as IP holder but no public pipeline activity. Are any academic groups pursuing this? Unclear.
  • Optimal cycling protocol. No published rationale; community guesses only.
▸ Sources (full, with our context)
Back to compact view